SEC Form 4 · accession 0001209191-17-029277

Ra Pharmaceuticals, Inc. · RARX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

10% Owner

10% Owner

Period of report

Feb 22, 2017

Accepted (ET)

May 2, 2017 · 5:22 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001481512

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1,F2	Feb 22, 2017	S	749	$21.8553	D	2,544,903	D
Common Stock^F1,F2	Feb 23, 2017	S	4,999	$21.0362	D	2,539,904	D
Common Stock^F1,F2	Feb 24, 2017	S	5,398	$20.9336	D	2,534,506	D
Common Stock^F1,F2	Feb 27, 2017	S	57,844	$20.9582	D	2,476,662	D
Common Stock^F1,F2	Feb 28, 2017	S	7,847	$20.8577	D	2,468,815	D
Common Stock^F1,F2	Mar 1, 2017	S	7,778	$20.9126	D	2,461,037	D

No Table II lines on this filing.

F1Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $21.85 to $21.88 on February 22, 2017; $20.74 to $21.32 on February 23, 2017; $20.85 to $21.01 on February 24, 2017; $20.85 to $21.09 on February 27, 2017; $20.50 to $21.06 on February 28, 2017; and $20.50 to $21.06 on March 1, 2017. The prices reported reflect the weighted average sale prices. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F2The board of directors of Novartis Bioventures Ltd. has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd. is an indirectly owned subsidiary of Novartis AG.